Doug J. Bartels - Concepedia

Author

Doug J. Bartels

Vertex Pharmaceuticals (United States)

Also Known As

D Bartels, D. Bartels, D.J. Bartels, Doug Bartels, Doug J Bartels, Doug J. Bartels, Doug J. Bartels

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Vertex Pharmaceuticals (United States)Janssen (Belgium)Janssen (United States)Cornell University Goethe University Frankfurt

About

Doug J. Bartels is an author at Vertex Pharmaceuticals (United States) specializing in medicine, viral hepatitis, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	734
2	Immunology	5	5	712
3	Hepatology	3	3	641
4	Health Sciences	1	1	51
5	Genetic Medicine	1	1	51

Doug J. Bartels

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir Christoph Sarrazin, Tara L. Kieffer, Doug J. Bartels, Gastroenterology HepatologyHepatitis CPatients TreatedViral HepatitisPhenotypic Changes	2007	611
Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects Doug J. Bartels, Yi Zhou, Eileen Z. Zhang, The Journal of Infectious Diseases	2008	206
Erf2, a Novel Gene Product That Affects the Localization and Palmitoylation of Ras2 in <i>Saccharomyces cerevisiae</i> Doug J. Bartels, David A. Mitchell, Xiangwen Dong, Molecular and Cellular Biology	1999	177
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials James C. Sullivan, Sandra De Meyer, Doug J. Bartels, Clinical Infectious Diseases	2013	164
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment Doug J. Bartels, James C. Sullivan, Eileen Z. Zhang, Journal of Virology	2012	144
Phenotypic Characterization of Resistant Val<sup>36</sup>Variants of Hepatitis C Virus NS3-4A Serine Protease Yi Zhou, Doug J. Bartels, Brian L. Hanzelka, Antimicrobial Agents and Chemotherapy	2007	94
Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants Yi Zhou, Ute Muöh, Brian L. Hanzelka, Journal of Biological Chemistry	2007	88
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials Tara L. Kieffer, Sandra De Meyer, Doug J. Bartels, PLoS ONE	2012	87
8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS J.C. Sullivan, Sandra De Meyer, Doug J. Bartels, Journal of Hepatology Health SciencesImmunologyClinical TrialsResistance Mutation (Virology)Antiviral Therapy	2011	51
<i>In Vitro</i> Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir Min Jiang, Nagraj Mani, Chao Lin, Antimicrobial Agents and Chemotherapy	2013	27

Page 1